Delivering Pharmaceutical Innovations Domestically and Globally
Toward Realizing the JPMA's Vision for 2035Our activities are centered on the three pillars of Innovation, Access, and Trust.
Consistently produce innovations to benefit health spans and the economy
-
Drug Evaluation Committee
"The Potential for Bioequivalence Evaluation Using Physiological Drug Absorption Models: The Current Status and Future Prospects of Virtual BE" has been published.
-
News Release
—Making Drug Discovery and Biotechnology Japan’s Engine of Growth— In Response to the Publication of the “Working Group Roadmap” by the Japan Growth Strategy Council
Bring innovative new drugs to the public more quickly to enhance health security
-
Consumer Consultation Review Committee
We have posted the “Medication Consultation Desk (for Healthcare Professionals).”
-
Drug Evaluation Committee
We have posted information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by Amendments to the Pharmaceutical and Medical Devices Act,’ to be held on March 17, 2026.”
Commit to ethical conduct and transparency to foster trust in the pharma industry
-
Pharmaceutical Industrial Policy Committee International Affairs Committee
We have posted “On Institutional Measures to Ensure a Stable Supply of Medicines and Other Products Necessary for Infectious Disease Control and to Promote Antimicrobial Drug Discovery.”
-
News Release Public Affairs Committee
Five Member Companies of the JPMA Participate in “Girls Meet STEM” — Each Company Hosts Its Own Program —
-
The latest issue of JPMA Newsletter features a special issue on "Biopharmaceuticals" and various other activities of JPMA.
-
Event Report: Updated July 1 Side event held in Geneva, Switzerland, during the World Health Assembly (WHA79)
-
DATA BOOK 2026" is now available.
-
Scientific and Practical Requirements for Drug Candidate Substances for Companies ~Statement of TPP
-
JPMA's Vision for 2035" and "JPMA's Policy Proposals for 2025" released on Feb. 26, 2025
Updates
-
Consumer Consultation Review Committee
We have posted the “Medication Consultation Desk (for Healthcare Professionals).”
-
Pharmaceutical Industrial Policy Committee International Affairs Committee
We have posted “On Institutional Measures to Ensure a Stable Supply of Medicines and Other Products Necessary for Infectious Disease Control and to Promote Antimicrobial Drug Discovery.”
-
Drug Evaluation Committee
"The Potential for Bioequivalence Evaluation Using Physiological Drug Absorption Models: The Current Status and Future Prospects of Virtual BE" has been published.
-
Drug Evaluation Committee
We have posted information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by Amendments to the Pharmaceutical and Medical Devices Act,’ to be held on March 17, 2026.”
-
International Affairs Committee Event Report
We have posted an article titled “Side Event Report — 79th World Health Assembly (WHA79)”
-
News Release
—Making Drug Discovery and Biotechnology Japan’s Engine of Growth— In Response to the Publication of the “Working Group Roadmap” by the Japan Growth Strategy Council
-
News Release
—Making Drug Discovery and Biotechnology Japan’s Engine of Growth— In Response to the Publication of the “Working Group Roadmap” by the Japan Growth Strategy Council
-
News Release Public Affairs Committee
Five Member Companies of the JPMA Participate in “Girls Meet STEM” — Each Company Hosts Its Own Program —
-
News Release
Top Leaders of Global Biopharmaceutical Companies Meet with Prime Minister Sanae Takaichi
-
Announcement Public Affairs Committee
The JPMA Newsletter May 2026 No. 229 is now available.
-
News Release APAC Project
On the Occasion of the 15th APAC (Asia-Pacific Association of Pharmaceutical Manufacturers) Conference
-
News Release APAC Project
The 15th APAC Press Conference
-
Consumer Consultation Review Committee
We have posted the “Medication Consultation Desk (for Healthcare Professionals).”
-
Pharmaceutical Industrial Policy Committee International Affairs Committee
We have posted “On Institutional Measures to Ensure a Stable Supply of Medicines and Other Products Necessary for Infectious Disease Control and to Promote Antimicrobial Drug Discovery.”
-
Drug Evaluation Committee
"The Potential for Bioequivalence Evaluation Using Physiological Drug Absorption Models: The Current Status and Future Prospects of Virtual BE" has been published.
-
Drug Evaluation Committee
We have posted information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by Amendments to the Pharmaceutical and Medical Devices Act,’ to be held on March 17, 2026.”
-
International Affairs Committee Event Report
We have posted an article titled “Side Event Report — 79th World Health Assembly (WHA79)”
-
News Release Public Affairs Committee
Five Member Companies of the JPMA Participate in “Girls Meet STEM” — Each Company Hosts Its Own Program —
-
International Affairs Committee Event Report
We have posted an article titled “Side Event Report — 79th World Health Assembly (WHA79)”
-
Pharmaceutical Industrial Policy Committee Event Report
Participation Report: “Yakusai 2026—A Science Experience Event for Children and Adults Alike”
-
Pharmaceutical Industrial Policy Committee Event Report
Report on the JPMA Media Forum: “The Diverse Value Brought by Innovative Medicines—Using Pediatric Acute Lymphoblastic Leukemia (ALL) as a Case Study”
-
Public Affairs Committee Event Report
Report on "The 45th Public Relations Seminar" is now available.
-
Drug Evaluation Committee Event Report
The 149th Assembly of the Drug Evaluation Committee" is now available.
-
Code Compliance Committee Event Report
The "FY2025 Meeting of Compliance Management Managers and Practitioners" was held.
About JPMA
Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders.
Each committee and specialized body bring together a diverse pool of talent - from young professionals to experienced experts - working across organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.
JPMA's Vision
Consistently produce innovations to benefit health spans and the economy
- Pharmaceutical innovations
- Leading-edge scientific technology
- Pharmaceutical manufacturing technology
- Domestic manufacturing infrastructure
- Making Japan a science and technology powerhouse
- Fostering highly skilled talent
- PPI/E
- Drug discovery that involves patients and the public
- Co-creation
- Drug discovery ecosystem
- Job creation
- Extending health spans
- Well being
- Pharma as a core industry
- Economic growth
Bring innovative new drugs to the public more quickly to enhance health security
- A social security system that gives patients swift access to “the latest treatments” and stable access to “global-standard treatments”
- Positive investment cycle
- Building an attractive domestic market
- Drug pricing that properly factors in the worth of innovation
- Health security for Japan
Commit to ethical conduct and transparency to foster trust in the pharma industry
- Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
- Overcome the social challenges raised by Japan’s aging population
- Ethical soundness, code of behavior, and transparency
- Boost public literacy in health and medicine
- Social significance of pharmaceuticals and the pharma industry
- Encourage the public and younger people to enter the pharma industry
- Climate change
- Environmental issues
Member Companies
The JPMA has 68 R&D-oriented JPMA member companies (as of June 1, 2026).
